| 标题： | 初诊IV期乳腺癌诊疗临床实践指南2022.V1 (CSBrS-Guideline-22) |
| title： | Clinical practice guideline for diagnosis and treatment of de novo stage lV breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2022 |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 中国乳腺疾病专业临床医生 |
| Guide users： | Clinicians specializing in breast diseases in China |
| 证据分级方法： | 本指南证据等级参考 GRADE系统，结合中国临床研究特点制定，将证据等级分为I、II、III、IV四类，量化体现指南编写专家对证据可靠性的评价情况。基于本指南在中国临床实践的可及性，专家组优先选择I类和II类证据纳入指南评价体系。 |
| Evidence grading method： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system |
| 制定单位： | 中华医学会外科学分会乳腺外科学组 |
| Formulating unit： | Chinese Society of Breast Surgery |
| 注册时间： | 2022-01-23 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN048 |
| Registration number： | |
| 指南制订的目的： | 为规范我国初诊IV期乳腺癌患者外科诊治策略，中华医学会外科学分会组织乳腺外科学专家参照GRADE（Grading of Recommendations Assessment,Development and Evaluation）方法对相关的临床研究证据质量进行评价，并结合中国乳腺外科临床实践的可行性，制定初诊IV乳腺癌诊疗临床实践指南（2022版），旨在为国内乳腺外科医师临床工作提供参考。 |
| Purpose of the guideline： | To standardize the surgical diagnosis and treatment of de novo stage IV breast cancer, the Chinese Society of Breast Surgery (CSBrS) evaluated the relevant evidences using the Grading of Recommendations Assessment, Development, and Evaluation system and combined the accessibility under China's national conditions and developed the Clinical practice guidelines for diagnosis and treatment of de novo stage lV breast cancer:Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021 with the aim of providing guidance to the clinical practices of breast surgeons in China. |
